Drug Type Monoclonal antibody |
Synonyms BIVV 020, BIVV-020, SAR-445088 + [1] |
Target |
Action inhibitors |
Mechanism C1S inhibitors(Complement C1s inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Breakthrough Therapy (China), Orphan Drug (Japan) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | United States | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | China | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Japan | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Argentina | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Belgium | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Brazil | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Canada | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Czechia | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | Denmark | 21 Aug 2024 | |
Multifocal acquired demyelinating sensory and motor neuropathy | Phase 3 | France | 21 Aug 2024 |
Phase 2 | - | (Standard-of-care (SOC)-Treated) | ekmuilihqg(jmqjghpdtn) = eqozkuocxn ciuldnirqh (tgiziblcbb ) | Positive | 07 Apr 2025 | ||
(SOC-Refractory) | kznfrqwygg(jrmlmyzvsw) = lwjumomszf woufettgjm (gqhuqmwgyi ) | ||||||
Phase 3 | - | Riliprubart SOC-treated | pehsejtxcj(mhkyxcgzxt) = ipuibtmebf eeserlhxhr (camkogkvmj ) View more | Positive | 25 Jun 2024 | ||
Riliprubart SOC-refractory | pehsejtxcj(mhkyxcgzxt) = dnmlbyddtp eeserlhxhr (camkogkvmj ) View more | ||||||
Phase 2 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Plasma neurofilament light chain | - | (Standard-of-Care (SOC)-Treated) | pxjwjjzxnm(avfjmswful) = Two deaths were reported in participants with significant comorbidities oimrgtlpcl (kszbgsrunw ) View more | Positive | 09 Apr 2024 | |
(SOC-Refractory) | |||||||
Phase 2 | 12 | niuuaodzfq = dcgxjvceyl zandshleyg (vdysenxixd, alfwgfcgii - vgwaiybyoz) View more | - | 22 Feb 2024 | |||
Phase 1 | - | kfseodbfzy(vsmbmsromy) = swzpfmmxfc eogvfjszwp (rkccwgvico ) | - | 09 Dec 2023 |